Search
All Clinical Trials
A listing of 23153 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 23153
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Recruiting
This study will investigate in patients with Crohn s disease and ulcerative colitis how the body s immune system controls inflammation in the gastrointestinal tract (stomach and intestines)-specifically, how lymphocytes (a type of white blood cell) function in inflammatory responses. This protocol does not involve any experimental treatments.
Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible fo... Read More
Gender:
ALL
Ages:
Between 1 day and 75 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Recruiting
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).
The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.
The study is looking at several other research questions, including:
* To see if odronextamab works to destroy cancer cells
* Side effects that may be experienced by people taking odronextamab
* How odronextamab works... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Rush University Medical Center, Chicago, Illinois +139 locations
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
Recruiting
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Duke University, Durham, North Carolina +7 locations
Conditions: Stress Urinary Incontinence
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/24/2025
Locations: Research Site, La Jolla, California +30 locations
Conditions: Advanced Solid Malignancies
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Recruiting
Background:
Myelodysplastic syndromes (MDS) are diseases that affect the bone marrow. They can inhibit the blood formation process and reduce blood cell counts. High-risk MDS can lead to leukemia. People with high-risk MDS have a low survival rate. Better treatments are needed.
Objective:
To test a study drug (KPT-8602), combined with another drug (Inqovi), in people with MDS.
Eligibility:
Adults aged 18 years and older with high-risk MDS that did not respond to treatment.
Design:
Partici... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myelodysplastic Syndromes
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
Recruiting
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to red... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Recruiting
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/24/2025
Locations: Research Site, Los Angeles, California +74 locations
Conditions: Non-small Cell Lung Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer:
* HR-positive (breast cancer cells that need estrogen or progesterone to grow)
* HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface);
* locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +85 locations
Conditions: Breast Cancer
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Recruiting
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require ne... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cysticercosis, Neurocysticercosis
Ischemic Conditioning Improves Walking Function Post Stroke
Recruiting
This innovative study will address scientific and clinical areas relatively unexplored in chronic stroke that could lead to greater recovery of walking. Ischemic Conditioning (IC) is a non-invasive, simple procedure that improves motor function, exercise performance and cardiovascular function in healthy controls, but it has never been applied to the stroke population. We postulate that IC enhances the recruitment of motoneurons and results in positive neural adaptations, improves vascular endot... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin +1 locations
Conditions: Stroke, Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Cardiovascular
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Recruiting
This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable Osteosarcoma
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Recruiting
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: City of Hope, Duarte, California +28 locations
Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
1 - 12 of 23153